The pharmaceutical world is observing a remarkable shift in diabetes treatment with the arrival of GLP-1 transdermal devices. These systems offer a potentially more user-friendly alternative to injections of GLP-1 drugs, minimizing the requirement of daily needle pricks. The innovation releases t